Out-licensing: Genetic disorders/Severe combined immunodeficiency

Latest: Watch here for details of new products and services.

Our Products: Overview; Partnering Search; Company Profiling; Partneringtools; Reports; Partnering Consulting; Comparison
Forums: Visit our forums
Jobs: Visit our job site
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire New!
Contact us: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing Ltd
is a division of

Up-to-date access to technology licensing opportunities worldwide.

Displaying 1..2 of 2 - per page
Order by

Sensitive and quantitative assay for the screening of trinucleotide repeat (TNR) mutations. More

A method of providing a therapeutic effect in human patients by administering to the patient CD34+ cells obtained from umbilical cord blood. More

Displaying 1..2 of 2 - per page
Order by

Therapeutic target: Genetic disorders del; Severe combined immunodeficiency del

Industry sector: Animal health; Biotechnology; Diagnostic; Drug delivery; Drug discovery; Medical device; Pharmaceutical; Research tools
Development phase: Early Stage; Preclinical; Phase I; Phase I/II; Phase II; Phase III; Phase III/IV; Preregistration; Registered

Industry news: Pharmalicensing provides comprehensive industry coverage.